Samsara BioCapital, L.P. → Mineralys Therapeutics, Inc. MLYS

Stake: 9.10% Shares: 5,736,305 CUSIP: 603170101 Class: Common Stock

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

3 transactions

0 buys · 1 sales · 2 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 5.73

8,370,090 shares short · -6.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $43.81M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-13	Congleton Jon	director, officer	Sale	15,730	$26.83	$422K
2026-04-13	Rodman David Malcom	officer	Option exercise	6,349	$1.08	$7K
2026-04-09	Rodman David Malcom	officer	Option exercise	2,170	$16.00	$35K

Other 13D/G Filings on Mineralys Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2025-03-17	SCHEDULE	RA CAPITAL MANAGEMENT, L.P.	9.90%	6,287,597	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →